Medicare price of Nilotinib

Nilotinib was approved in 2007 for the treatment of imatinib-resistant CML-CP based on the results of the trial. Subsequently, in 2010, based on the results of the pivotal phase ENESTnd study, it was approved by the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) and health authorities in multiple countries around the world for the treatment of newly diagnosed patients with chronic myelogenous leukemia.

The original drug of nilotinib was marketed in China under the name of nilotinib, with the trade name of Daxina, and subsequently entered the scope of medical insurance, but reimbursement was limited to patients who met the indications, including newly diagnosed Ph+CML-CP adult patients and children over 2 years old; and previous treatment (including imatinib For adult patients with drug-resistant or intolerant Ph+CML-CP and CML-AP, as well as pediatric patients over 2 years old in the chronic phase, the price per box of 150mg*120 capsules may be around RMB 9,000. The reimbursement ratio is different in different regions, and the price after reimbursement may be different. Patients can consult the local medical insurance bureau or hospital.

The brand name of the original nilotinib drug marketed overseas is Tasigna. The price of the original Indian version of nilotinib, 150mg*28 tablets per box, may be around 1,000 yuan per box, and the price is 200mg* The price of each box of 28 pills may be around RMB 2,000 (the price may fluctuate due to the exchange rate). The ingredients of the original drugs sold domestically and abroad are basically the same. There is currently no generic version of Nilotinib on the market. For more drug information and specific prices, please consult Yaode Medical Consultants.